Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Patent
• Report
• Software

Filter by year:

Filter from 2024202320222021202020192018201720162015201420132012201120102009200820072006 to Filter to 2024202320222021202020192018201720162015201420132012201120102009200820072006

---

Search results

• Journal article
  McIlroy JR, Mullish BH, Goldenberg SD, Ianiro G, Marchesi JRet al., 2020,

  Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?

  , Clinical Immunology, ISSN: 1521-6616
  • Cite
• Journal article
  Vieira-Silva S, Falony G, Belda E, Nielsen T, Aron-Wisnewsky J, Chakaroun R, Forslund SK, Assmann K, Valles-Colomer M, Nguyen TTD, Proost S, Prifti E, Tremaroli V, Pons N, Le Chatelier E, Andreelli F, Bastard J-P, Coelho LP, Galleron N, Hansen TH, Hulot J-S, Lewinter C, Pedersen HK, Quinquis B, Rouault C, Roume H, Salem J-E, Sondertoft NB, Touch S, Dumas M-E, Ehrlich SD, Galan P, Gotze JP, Hansen T, Holst JJ, Kober L, Letunic I, Nielsen J, Oppert J-M, Stumvoll M, Vestergaard H, Zucker J-D, Bork P, Pedersen O, Backhed F, Clement K, Raes Jet al., 2020,

  Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

  , NATURE, Vol: 581, Pages: 310-+, ISSN: 0028-0836
  • Author Web Link
  • Cite
  • Citations: 201
• Journal article
  Ianiro G, Mullish BH, Kelly CR, Sokol H, Kassam Z, Ng SC, Fischer M, Allegretti JR, Masucci L, Zhang F, Keller J, Sanguinetti M, Costello SP, Tilg H, Gasbarrini A, Cammarota Get al., 2020,

  Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel

  , The Lancet Gastroenterology & Hepatology, Vol: 5, Pages: 430-432, ISSN: 2468-1253
  • Publisher Web Link
  • Open Access Link
  • Cite
• Journal article
  Allegretti JR, Hurtado J, Carrellas M, Marcus J, Nemes S, Marchesi J, Mullish BH, McDonald JA, Phelps EL, Sagi S, Bohm M, Geradin Y, Silverstein M, Kelly CR, Kassam Z, Grinspan A, Fischer Met al., 2020,

  121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICLE INFECTION

  , Gastroenterology, Vol: 158, Pages: S-22, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Conference paper
  Martinez-Gili L, McDonald JA, Liu Z, Kao DH, Allegretti JR, Barker GF, Blanco JM, Holmes E, Thursz MR, Marchesi J, Mullish BHet al., 2020,

  644 identification of novel changes in microbially-derived metabolites after fecal microbiota transplant for recurrent clostridioides difficile infection

  , Publisher: Elsevier BV, Pages: S-138-S-139, ISSN: 0016-5085
  • Publisher Web Link
  • Open Access Link
  • Cite
• Conference paper
  Ghani R, Mullish BH, McDonald JA, Ghazy A, Williams HR, Brannigan E, Satta G, Gilchrist M, Duncan N, Corbett R, Pavlu J, Innes AJ, Thursz MR, Davies F, Marchesi Jet al., 2020,

  1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION

  , Publisher: Elsevier BV, ISSN: 0016-5085
  • Cite
• Journal article
  Allegretti JR, Kassam Z, Hurtado J, Carrellas M, Marchesi J, Mullish BH, Chiang AL, Cummings BP, Thompson CCet al., 2020,

  Tu1909 IMPACT OF FECAL MICROBIOTA TRANSPLANTATION ON PREVENTION OF METABOLIC SYNDROME AMONG PATIENTS WITH OBESITY

  , Gastroenterology, Vol: 158, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Journal article
  Monaghan T, Russell L, Rosati E, Mullish BH, Roach B, Wong K, Wong GK, Polytarchou C, Franke A, Marchesi J, Kao DHet al., 2020,

  Mo1939 TEMPORAL MODULATION OF TCR REPERTOIRE FOLLOWING SEQUENTIAL FMT TREATMENT IN PATIENTS WITH SEVERE OR FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION

  , Gastroenterology, Vol: 158, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Journal article
  Blanco JM, Liu Z, Selvarajah U, Mullish BH, Alexander JL, McDonald JA, Abraham S, Marchesi Jet al., 2020,

  Sa1923 identification of new associations between psoriatic arthritis and the gut microbiota, a phenomic study

  , Gastroenterology, Vol: 158, Pages: S-481, ISSN: 0016-5085
  • Publisher Web Link
  • Cite
• Journal article
  Allegretti JR, Kassam Z, Mullish BH, Chiang A, Carrellas M, Hurtado J, Marchesi JR, McDonald JAK, Pechlivanis A, Barker GF, Miguens Blanco J, Garcia Perez I, Wong WF, Gerardin Y, Silverstein M, Kennedy K, Thompson Cet al., 2020,

  Effects of fecal microbiota transplantation with oral capsules in obese patients

  , Clinical Gastroenterology and Hepatology, Vol: 18, Pages: 855-863.e2, ISSN: 1542-3565

  Background & AimsStudies in mice have shown that the intestinal microbiota can contribute to obesity via the anorexigenic gut hormone glucagon-like peptide 1 (GLP1) and bile acids, which affect lipid metabolism. We performed a randomized, placebo-controlled pilot study of the effects of fecal microbiota transplantation (FMT) in obese, metabolically uncompromised patients.MethodsWe performed a double-blind study of 22 obese patients (body mass index [BMI] ≥ 35kg/m2) without a diagnosis of diabetes, non-alcoholic steatohepatitis, or metabolic syndrome. Participants were randomly assigned (1:1) to groups that received FMT by capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8) or placebo capsules. FMT capsules were derived from a single, lean donor (BMI, 17.5 kg/m2). Patients were followed through week 26; the primary outcome was safety. Stool and serum samples were collected from patients at baseline and at weeks 1, 4, 6, 8 and 12 after administration of the first dose of FMT or placebo and analyzed by 16S RNA gene sequencing. Stool and serum samples were analyzed for metabolomics by liquid chromatography-mass spectrometry. Additional outcomes were change in area under the curve for GLP1 at week 12.ResultsWe observed no significant differences in adverse events between patients who received FMT vs placebo. There was no increase in the area under the curve of GLP1 in either group. Patients who received FMT had sustained shifts in microbiomes associated with obesity toward those of the donor (P<.001). Patients who received FMT had a sustained decrease in stool levels of taurocholic acid (P<.05), compared with baseline; bile acid profiles began to more closely resemble those of the donor. We did not observe significant changes in mean BMI at week 12 in either group.ConclusionsIn a placebo-controlled pilot study, we found that FMT capsules (derived from a lean donor) were safe but did not reduce BMI in obese metabol

  • Abstract
  • Publisher Web Link
  • Open Access Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.